Literature DB >> 25882081

Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.

Dimah Saade1, Charuta Joshi2.   

Abstract

BACKGROUND: Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalographic discharges, developmental deterioration, and early mortality. Recent widespread interest in the nonpsychoactive component of the cannabis plant, cannabidiol, as a potential treatment for refractory devastating epilepsies has led to individual trials initiated by families or physicians in states that have legalized medical marijuana with anecdotal success. PATIENT DESCRIPTION: We describe a now 10-month-old boy with malignant migrating partial seizures in infancy who made developmental gains and demonstrated sustained seizure reduction with the addition of cannabidiol to his antiepileptic regimen.
CONCLUSION: This report supports a role for cannabidiol in the treatment of malignant migrating partial seizures in infancy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CBD; cannabidiol; ketogenic diet; malignant migrating partial epilepsy; migrating partial seizures

Mesh:

Substances:

Year:  2015        PMID: 25882081     DOI: 10.1016/j.pediatrneurol.2015.02.008

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  8 in total

Review 1.  Marijuana Use in Epilepsy: The Myth and the Reality.

Authors:  Kamil Detyniecki; Lawrence Hirsch
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

Review 2.  Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature.

Authors:  Gabriela Araujo Moreira; Roddie Moraes Neto; Ricardo Gullit Ribeiro; Ana Chrystina De Souza Crippa
Journal:  Rev Paul Pediatr       Date:  2022-07-06

Review 3.  Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities.

Authors:  Dinesh Upadhya; Olagide W Castro; Raghavendra Upadhya; Ashok K Shetty
Journal:  Mol Neurobiol       Date:  2018-01-25       Impact factor: 5.590

4.  Cannabis Use for Therapeutic Purposes by Children and Youth at a Tertiary Teaching Hospital in Canada: A Retrospective Chart Review.

Authors:  Régis Vaillancourt; Maria Moreno; Annie Pouliot; Erick Sell
Journal:  Can J Hosp Pharm       Date:  2020-04-01

5.  A systematic review of cannabidiol dosing in clinical populations.

Authors:  S A Millar; N L Stone; Z D Bellman; A S Yates; T J England; S E O'Sullivan
Journal:  Br J Clin Pharmacol       Date:  2019-07-19       Impact factor: 4.335

6.  Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.

Authors:  Simona Lattanzi; Eugen Trinka; Pasquale Striano; Chiara Rocchi; Sergio Salvemini; Mauro Silvestrini; Francesco Brigo
Journal:  CNS Drugs       Date:  2021-03-22       Impact factor: 5.749

Review 7.  Channelopathy of Dravet Syndrome and Potential Neuroprotective Effects of Cannabidiol.

Authors:  Changqing Xu; Yumin Zhang; David Gozal; Paul Carney
Journal:  J Cent Nerv Syst Dis       Date:  2021-12-20

Review 8.  Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?

Authors:  Emilio Perucca
Journal:  J Epilepsy Res       Date:  2017-12-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.